Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S...(l sale of the U.S. business and Encorium...)

Date:7/1/2009

l sale of the U.S. business and Encorium OY and our expectations regarding the effects of such transactions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the timing of the closing, if any, of the transactions; (ii) the completion to the purchasers satisfaction of due diligence; (iii) the acquisition by us of a fairness opinion relating to the purchase price for the sale of Encorium OY; (iv) our ability to negotiate definitive agreements with the Purchasers; (v) the possibility that the transactions may not close; and (vi) the risk that any distributions to stockholders in connection with the transactions will be significantly less than the current stock price.

Additional risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and price
'/>"/>

SOURCE Encorium Group, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Avicena Group to Present at Noble Financial Conference
9. Chrome Group to Seek Listing for Some of its Subsidiaries
10. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
11. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy